Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Doctor reading study on laptop

Key Imaging Features for Differentiating Rare Pancreatic Tumors

Solid pseudopapillary neoplasms (SPN), also known as Frantz tumors, are rare tumors of the pancreas. Due to overlapping features of SPN and pancreatic neuroendocrine neoplasms (pNEN), distinguishing between them using imaging can prove challenging.

Researchers at the University Hospital Heidelberg conducted a study to differentiate SPN from pNEN using preoperative CT and MRI scans. They analyzed the imaging data of 39 SPN patients and 127 pNEN patients.

The study identified three key features that enable differentiation between SPN and pNEN: younger patient age, lack of contrast enhancement in the arterial phase, and the presence of a capsule. These features are easily applicable in routine diagnostics and could help prevent misdiagnoses.

Read more here.

Related Resources

Related Resources

AI lung nodules detection in contextflow and Lung-RADS in mint Lesion

Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care

Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule…

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…